MicuRx

MicuRx is a biopharmaceutical company focusing on novel therapeutics for infectious diseases. With global independent intellectual property and competitiveness, we are committed to the discovery, development, and commercialization of innovative drugs for unmet medical needs. Since the company was founded in 2007, MicuRx has adhered to the principle of “Better therapy through superior medicine", focusing on the increasingly serious problem of global antimicrobial resistance. With the core competitiveness of solving clinical problems and differentiated innovation, our goal is to be a respected leader in the field of innovative medicines, to provide superior and differentiated therapeutic products to patients.

MicuRx has established R&D centers in both China and the US, with an international core R&D team. Key members of our R&D team have rich experience in international innovative drug development and management, and have led or participated in the development of a number of marketed antimicrobial new drugs. MicuRx insists on the self-development strategy, concentrates in specialized fields, and has established an integrated antibacterial new drug R&D system covering early design and screening of innovative drugs, preclinical evaluation, global clinical development, manufacturing management, and regulatory affairs. Following international practice and standards, the company succeeds with the China-US parallel development strategy.

The company’s first antibacterial product, Contezolid, is a next-generation oxazolidinone antibiotic independently designed and developed by the company. It is intended for the treatment of infections caused by multidrug-resistant Gram-positive bacteria. Contezolid has successfully completed Phase I, II, and III clinical trials in China, Phase I clinical trials in Australia, and Phase II clinical trials in the US. On June 1, 2021, it was approved for marketing by the National Medical Products Administration (NMPA) under the priority review and approval process. In December 2021, it was included in the National Reimbursement Drug List (Category B) and successfully renewed in 2023. Clinical trials to expand its use to pediatric patients are currently underway. The clinical trials of Contezolid in China have implemented several pioneering initiatives, laying a solid foundation for improving clinical trial standards and product quality in the field of innovative antibacterial drugs in China.

MRX-4 is a water-soluble prodrug of Contezolid, which is converted into Contezolid in the body to exert its therapeutic effect. A global multi-center Phase III clinical trial of MRX-4 in sequential use with Contezolid is currently ongoing. MRX-8, designed for the treatment of multidrug-resistant Gram-negative bacterial infections, has completed Phase I clinical trials in both the United States and China.

In addition to these three core products that have entered the clinical and/or commercialization stages, the company has several other anti-drug-resistant bacterial drugs, as well as drugs targeting kidney cancer and nephritis, in the preclinical stage.